Flush with cash from their GLP-1 franchises, Eli Lilly and Novo Holdings have become the most active participants in Series A biotech funding. They are leveraging their deep pockets to stimulate company formation and strategically branch into new therapeutic areas, shaping the next wave of innovation.

Contrary to modern finance theory, companies owned by non-profit foundations demonstrate superior long-term financial performance, longevity (6x more likely to reach 50 years), and return on assets compared to conventionally structured, shareholder-first corporations.

Following the two-tiered model of companies like Novo Nordisk, AI safety startup Anthropic established a 'Long-Term Benefit Trust.' This perpetual purpose trust has outside trustees who can appoint directors to the main board, ensuring the company remains aligned with its core mission.

An alternative corporate structure where a for-profit company is overseen by a nonprofit foundation (e.g., Zeiss, Novo Nordisk, Hershey's) dramatically increases longevity. Data shows these companies have a 60% chance of reaching age 50, versus just 10% for conventional firms.

Unlike publicly traded competitors, Servier's non-profit foundation ownership insulates it from short-term investor pressures. This freedom enables a long-term strategic focus, allowing the company to pursue high-risk, scientifically complex areas like rare oncology that public companies often cannot justify to shareholders.

Novo Nordisk's head-to-head trial of its Cagracemma against Lilly's Zepbound was a major strategic error. Instead of demonstrating superiority, the study showed Zepbound was more effective, wiping $26 billion from Novo's market cap. Novo effectively funded a large-scale clinical trial that validated its primary competitor's product.

Novo Nordisk's pursuit of obesity drug developer Metcera wasn't a bidding war. CEO Mike Dustar explained they made one disciplined $10B offer from the start and held it through 16 bids, letting Pfizer ultimately pay more because it wasn't worth more to them.

The merger of Novozymes and Chr. Hansen wasn't a typical cost-synergy play. They maintained their combined R&D spending ratio to proliferate their pipeline, using complementary technologies to solve problems neither company could address alone.

Vivtex's $2.1B deal with Novo Nordisk wasn't from a single pitch; it was cultivated over many years, stemming from pre-existing academic relationships. The key was building mutual scientific trust by consistently sharing progress—and even failures—allowing Novo Nordisk to observe their journey long-term.